KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 5,354 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 5,354 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $83,361.78. Following the sale, the insider owned 138,983 shares in the company, valued at $2,163,965.31. The trade was a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV traded up $0.21 during midday trading on Tuesday, reaching $15.77. 751,567 shares of the company traded hands, compared to its average volume of 635,299. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.23 and a twelve month high of $19.00. The firm has a market capitalization of $797.17 million, a price-to-earnings ratio of -3.99 and a beta of -0.19. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company has a fifty day moving average price of $15.47 and a 200 day moving average price of $13.94.

Analyst Ratings Changes

Several research firms have commented on KALV. HC Wainwright upped their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Citizens Jmp reduced their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 11th. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Finally, TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $29.40.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Emerald Advisers LLC lifted its holdings in KalVista Pharmaceuticals by 30.2% in the 3rd quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock valued at $16,458,000 after acquiring an additional 313,205 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in shares of KalVista Pharmaceuticals by 26.4% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock valued at $8,693,000 after purchasing an additional 160,759 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in shares of KalVista Pharmaceuticals by 364.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $1,130,000 after purchasing an additional 78,450 shares in the last quarter. F m Investments LLC raised its holdings in shares of KalVista Pharmaceuticals by 263.8% in the 2nd quarter. F m Investments LLC now owns 182,262 shares of the specialty pharmaceutical company’s stock worth $2,060,000 after purchasing an additional 132,165 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ lifted its stake in KalVista Pharmaceuticals by 391.9% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock valued at $2,449,000 after purchasing an additional 160,128 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.